Lucitanib

Generic Name: Lucitanib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₅N_₃O_₄

CAS Number: 1058137-23-7

Unique Ingredient Identifier: PP449XA4BH

Background: Lucitanib has been used in trials studying the treatment of ER+, MBC, SCLC, HER2+, and NSCLC, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Mantle Cell Lymphoma Clinical Trial Pipeline Insights Featuring 20+ Companies

Mantle cell lymphoma (MCL) treatment outcomes improve with novel targeted therapies like BTK inhibitors. DelveInsight's 'Mantle Cell Lymphoma Pipeline Insight 2024' covers 20+ companies developing 22+ therapies, including Venetoclax and ADI-001. Key events include AstraZeneca's Phase III ECHO trial and BeiGene's AACR presentation.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy